Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

This study has been terminated.
(Hoag Hospital ceased support.)
Information provided by (Responsible Party):
Caladrius Biosciences, Inc. Identifier:
First received: December 24, 2008
Last updated: June 30, 2014
Last verified: June 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2011
  Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)